Sensex Bottom Target: UPA gap



Disclaimer:

I am a trained Medical Professional. 
I am still not sure if I am fully qualified to deal with issues pertaining to Medical Profession,
forget about giving opinions on Economics, Sociology & Geopolitics. Hence what I write / think are my own personal views, to be read by the readers at their own risk with dollops of salt and....pepper.

Revisit old news: Zeenews Bureau

Mumbai, May 18: With the Congress-led UPA getting enough numbers to form a stable and progressive government at the Centre, buoyancy returned to the stock markets as both the Sensex and Nifty surged on Monday.
The benchmark 30-share Sensex jumped 2099 points today and was trading at 14,479 when the trading was halted. The trading was resumed at 11:55 am after being halted in the morning but the further jump and the breaching of the 20% circuit breaker the trading was haled for the day.
(http://zeenews.india.com/news/business/markets-cheer-upa-sensex-crosses-14k_532573.html)

Sensex Target : The UPA gap.
When UPA II came to power, minus the left front, the markets gave it a booming salute.
From about 12500 it jumped straight to 14500.
With UPA II's  performance not worthy of the salute,
The market will retrace back to fill this gap. 
(According to Technical analyst: " will come back to fill the gap")
So the target, for the bottom of the Sensex, could be between 12500 to 13000
Reasons could be 
Local (Fall of UPA govt.) or
Global: (Double dip recession, a repeat of 1940's)

Today ( 08/09/2011) Sensex is at 17200


Comments

Post a Comment

Popular posts from this blog

Aab Tak Chhapan, Aab Nahi to Kab?

Image
I am 56, if not now then when? "If I can, anybody can". India has become the capital of Obesity, Diabetes and Osteoporosis  due to lack of motivation for Outdoor activity. "If you Desire change, change yourself first". I used to advise patients to opt for a active outdoor life. But nobody listened. As a Surgeon at 56, aspiring to be a role model for wellness and fitness I participated in the Polar Fjallraven 2018 contest. Few years back on reaching 50s, I had lot of problems. Syndrome X, Midlife crisis, Mid WAIST crisis, Mid leg crisis and what not. I had the option of taking the Stick – wooden, aluminium, medicine !! I opted for two sticks instead of one. The stick of Running and Hiking. Over the past five years I have played Squash, Lifted weights done a few Half Marathons,Skied and Trekked. Local treks ( Ghatkopar Tekddi, Mulund Tekddi, Sahayadri Ghats and Forts and then high altitude mountain treks in India and Nepa...
Read more

#celebrating60s. Atmanirbhar 41 kms run. 5 th Dec 2021

#celebrating60s Atmanirbhar 41 kms run. Self supported Run. Nutrition, hydration, illumination and music all carried on back. Thanks K Sanjay Singh for giving company in the last 5 kms, pacing and helping me climb the "wall". I dedicate the Run to Dr Pranesh Patil Gaikwad, senior Anesthetist Ghatkopar, fellow runner, co trekker, and travel buddy, with a prayer.. recover soon dear friend. I continuously prayed for him during the run and could finish the run smoothly. The collective prayer of all will smoothen his recovery. We have travelled to many places together, but many are still on the bucket list. Recover soon Patil so I can begin planning.
Read more

Cipla Embraces Gilead and a New Era as Priorities Change

Cipla Embraces Gilead and a New Era as Priorities Change Divya Rajagopal Mumbai:   Once a steadfast backer of generics, co now enters into a deal to make Hepatitis drug for MNC ruary last year Hamied had said  In an interview to ET in 2013, YK Hamied, the founder chairm an of Cipla, and some say the scourge of multinational drug companies, prophesied that the Indian drug industry will witness a sea change around the year 2020.“The momentum of 1972 to 1995 (pre-patent era) can't stop . It will last till 2015, but not after that. So to protect myself for 2020 I have to make radical changes.“ On Monday , the world got a glimpse of the kind of change that Hamied had in mind when Cipla teamed up with California-based Gilead Lifesciences to make and sell its path-breaking Hepatitis C drug Sofosbuvir under voluntary licence. On the face of it, there is nothing wrong with this kind of a deal.Pharma companies ink many such pacts on a regular basis. But what...
Read more